A clinical evaluation revealed that adavosertib in combination with neoadjuvant cisplatin and docetaxel was safe and well-tolerable and showed promising antitumor efficacy in patients with advanced HNSCC, implicating Wee1-targeting as a potential regimen for this disease [73]. This evidence concerns the gene WEE1 and head and neck squamous cell carcinoma.